Karyopharm Therap(KPTI.US)

Last Updated 19:00:00 ET
longbridge loading

Karyopharm (KPTI) Leans on SENTRY in Pivotal Call

Tip Ranks·
US
KPTI
+1.63%
US
IHE
+0.69%
US
XBI
+0.66%
Tip Ranks·
US
KPTI
+1.63%
US
IHE
+0.69%
US
XBI
+0.66%

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

benzinga_article·
US
WOK
-22.17%
US
MTVA
-0.69%
US
VRAX
-5.58%
benzinga_article·
US
WOK
-22.17%
US
MTVA
-0.69%
US
VRAX
-5.58%

Karyopharm Therapeutics shares are trading lower. The company reported its Q1 financial results.

benzinga_article·
US
KPTI
+1.63%
US
FBT
+0.52%
US
IHE
+0.69%
benzinga_article·
US
KPTI
+1.63%
US
FBT
+0.52%
US
IHE
+0.69%

RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)

Tip Ranks·
US
KPTI
+1.63%
US
IBB
+0.62%
US
BIB
+0.08%
Tip Ranks·
US
KPTI
+1.63%
US
IBB
+0.62%
US
BIB
+0.08%

Karyopharm Therapeutics Inc. Stock 12‑Month Price Target Raised to $15, Implies 69% Upside

TradingView·
US
KPTI
+1.63%
TradingView·
US
KPTI
+1.63%

Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript

benzinga_article·
US
KPTI
+1.63%
US
VHT
+0.40%
US
PBE
+0.33%
benzinga_article·
US
KPTI
+1.63%
US
VHT
+0.40%
US
PBE
+0.33%

Karyopharm Therapeutics Inc. 1Q 2026: Revenue $35.1M, EPS $(1.24) — 10-Q Summary

TradingView·
US
KPTI
+1.63%
US
XBI
+0.66%
US
XLV
+0.39%
TradingView·
US
KPTI
+1.63%
US
XBI
+0.66%
US
XLV
+0.39%

Karyopharm Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 35.07 M

Earnings Watch·
US
KPTI
+1.63%
Earnings Watch·
US
KPTI
+1.63%

Karyopharm Reports First Quarter 2026 Financial Results and Completion of Phase 3 Endometrial Cancer Trial Enrollment | KPTI Stock News

StockTitan·
US
KPTI
+1.63%
US
XLV
+0.39%
US
SBIO
+1.57%
StockTitan·
US
KPTI
+1.63%
US
XLV
+0.39%
US
SBIO
+1.57%
© 2026 Longbridge｜Disclaimer